课件：老年晚期肺癌患者的药物选择.ppt

* [7]Rossi D, Dennetta D, Ugolini M, et al. Weekly paclitaxel in elderly patients (aged or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study[J]. Clin Lung Cancer, 2008, 9(5): 280-284. Rossi D, et al.Clin Lung Cancer, 2008, 9(5): 280-284. * [8]Martoni A, Di Fabio F, Guaraldi M, et al. Prospective phase Ⅱ study of single agent gemcitabine in untreated elderly patients with stage Ⅲ B/ Ⅳ non-small-cell lung cancer[J]. Am J Clin Oncol, 2001, 24(6): 614-617. Martoni A,et al.Am J Clin Oncol, 2001, 24(6): 614-617. * * [9]Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase Ⅲrandomized trial[J]. J Natl Cancer Inst, 2003, 95(5): 362-372. Gridelli C, et al. J Natl Cancer Inst, 2003, 95(5): 362-372. * * * * [10]蒋京伟，梁晓华，周鑫莉，等 . 卡铂与顺铂治疗晚期非小细胞肺癌疗效的荟萃分析[J]. 中华医学杂志，2006，86（37）：2615-2620. [11]Hiroshi Takatani, Yoichi Nakamura, Seiji Nagashima, et al. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non–small-cell lung cancer[J]. Clin Lung Cancer, 2012 Jan 18. [10]蒋京伟，等 . 中华医学杂志，2006，86（37）：2615-2620. [11]Hiroshi Takatani, et al. Clin Lung Cancer, 2012 Jan 18. * [12]Resell R，Carcereny E，Gervais R，et a1．Erlotinib versus standard chemotherapy as first—line treatment for European patients with advanced EGFR mutation-positive non-smal1．eell lung cancer(EURTAC)：a muhicentre，open—label。randomised phase 3 trial[J]．Lancet Once1，2012，3(3)：239-246. [12]Resell R，et a1．Lancet Once1，2012，3(3)：239-246. * [13]Khozin S，Blumenthal GM，Jiang X，et a1．U．S．Food and Drug Administration approval summary： Erlotinib for the first—line treatment of metastatic non—small eell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 2l (L858R) substitution mutations